Raymond J Bergeron

Chief Scientific Officer & Founder at AbFero Pharmaceuticals

Internationally recognized as a pioneer of iron chelator technology, Dr. Raymond Bergeron is Chief Scientific Officer and a founder of AbFero Pharmaceuticals. Dr. Bergeron is Professor Emeritus, Medicinal Chemistry and Duckworth eminent scholar of drug development, University of Florida, and is a Charter Fellow of the National Academy of Inventors (NAI). Dr. Bergeron has dedicated his career to drug discovery and development in iron overload diseases and cancer with prolific results: he has published more than 200 papers, generated more than 200 patents, and six of his discoveries have reached human clinical trials. Dr. Bergeron graduated from Clark University, earned his Ph.D. in chemistry from Brandeis University, and was a post-doctoral fellow with Nobel Laureate Konrad Bloch at Harvard University.


Org chart


Teams


Offices

This person is not in any offices


AbFero Pharmaceuticals

AbFero Pharmaceuticals is a privately held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload. Their therapeutic platform addresses transfusion-related iron overload (TIO) and iron accumulation associated with diseases of aging, such as age-related macular degeneration (AMD), and Parkinson’s disease.


Industries

Employees

1-10

Links